BMRN News and Press, BioMarin Pharmaceutical Inc. From 04/23/24

2024-04-23 17:20:33 ET More on BioMarin Pharmaceutical BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript ...

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexand...

2024-04-10 03:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-21 03:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting PR Newswire Investigator-Sponsored Phase 2 Study Demonstrat...

2024-03-10 03:56:46 ET Summary Third Point's portfolio is still top-heavy, with 10 stocks making up 70% of its AUM. The fund made a large trade by purchasing shares of Verizon and closing out its T-Mobile position. Third Point reduced its positions in Uber, Taiwan Semiconducto...

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer PR Newswire Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif. ...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-03-05 22:43:45 ET Summary Dan Loeb's 13F portfolio value increased to $6.64B this quarter, with the top three holdings accounting for ~37% of the portfolio. Third Point returned 3.4% in 2023 compared to 26.3% for the S&P 500 Index. New stakes include Fleetcor Tech, Ve...

BioMarin Scheduled to Participate in March Investor Conferences PR Newswire - Cowen 44 th Annual Healthcare Conference on March 5 -       Leerink Partners Global Biopharma Conference on March 11 -    ...